 WATERTOWN, Mass.--BUSINESS WIRE--Forma Therapeutics Holdings, Inc. Nasdaq: FMTX, a clinical-stage biopharmaceutical company focused on sickle cell disease, prostate cancer and other rare hematologic diseases and cancers, today announced positive initial results from a Phase 1 trial of its novel CBPp300 inhibitor, the oral small molecule FT-7051, in men with metastatic castration-resistant prostate cancer mCRPC. Initial clinical data from the Courage Study, an ongoing first-in-human Phase 